Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements
Authors:
- Massimiliano PacilioMPMassimiliano Pacilio
- Luciano BianciardiLBLuciano Bianciardi
- Vincenzo PanichelliVPVincenzo Panichelli
- Giovanni ArgiròGAGiovanni Argirò
- Cesidio CiprianiCCCesidio Cipriani
- 1 July 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 26 (7) , 623-631
Abstract
To provide a comprehensive overview with regard to the hospitalization/discharge planning and nursing staff requirements for the management of patients treated with radioiodine for differentiated thyroid carcinoma. A statistical analysis of the fast clearance phase of 131I was performed in 265 hospitalized patients treated after total thyroidectomy with fixed doses ranging from 2590 to 9250 MBq. Two hundred and twenty-five cases were post-surgical ablation treatments and 40 cases were follow-up treatments. The 131I clearance was studied during hospitalization of 2-4 days. No clearance differences were found between the two groups. The median value of the biological half-time (T1/2bio) was 0.65 days, with a variability range of 0.30-2.03 days. A statistical model for the distribution of T(1/2bio) was reported. Some patients on maintenance haemodialysis were also studied, with T(1/2bio) values ranging from 1.6 to 2.6 days. The weekly cumulative dose to personnel from external exposure, corresponding to the 95th percentile, ranged from 0.1 mSv per GBq of administered activity (mSv x GBq(-1)) with a totally ambulant patient to 5.4 mSv . GBq with a totally helpless patient. With patients on maintenance haemodialysis, these values could increase from 1.2 to 1.7 times. The cumulative dose to close relatives was also estimated. The hospitalization times associated with 75% and 95% probabilities of patient discharge were calculated by varying the residual activity limit from 100 to 800 MBq. Finally, using the median T(1/2bio), personnel requirements were evaluated. With totally ambulant and semi-ambulant patients, about 0.5 and 1.0 personnel units per GBq of weekly administered activity were needed so as not to exceed an annual planning dose of 6 mSv per year. The treatment of patients with higher degrees of dependency was impractical. On the basis of statistical analysis, a better organization of in-patient treatment may be obtained, as well as more accurate preliminary evaluations of the cumulative doses to nursing staff and attending personnel, for the management of patients treated with radioiodine for differentiated thyroid carcinoma.Keywords
This publication has 13 references indexed in Scilit:
- Differentiated thyroid cancer: radioiodine following lobectomy — a clinical feasibility studyNuclear Medicine Communications, 2004
- Influence of diagnostic and therapeutic doses on thyroid remnant ablation ratesNuclear Medicine Communications, 2003
- Disposition of Radioiodine 131I Therapy for Thyroid Carcinoma in a Patient with Severely Impaired Renal Function on Chronic Dialysis: a Case ReportJapanese Journal of Clinical Oncology, 2002
- Dosimetrically Determined Doses of Radioiodine for the Treatment of Metastatic Thyroid CarcinomaThyroid®, 2002
- Post-surgical ablation of thyroid remnants with high-dose 131I in patients with differentiated thyroid carcinomaNuclear Medicine Communications, 2001
- Risk assessment of the nuclear medicine patient.British Journal of Radiology, 1997
- Radioiodine Treatment of Thyroid Carcinoma in Patients on Maintenance HemodialysisThyroid®, 1996
- Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroidEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Management of Thyroid Papillary Carcinoma With Radioiodine in a Patient With End Stage Renal Disease on HemodialysisClinical Nuclear Medicine, 1994
- Estimation of close contact doses to young infants from surface dose rates on radioactive adultsNuclear Medicine Communications, 1987